Oncotarget recently #published this #editorial perspective in Volume 14, entitled, “C/EBPβ cooperates with MYB to maintain the oncogenic program of AML cells." @uni_muenster DOI - https://t.co/fzl5bTnDY2 #cancer #aml #research #openaccess #publishing #o
Oncotarget recently #published this #editorial perspective in Volume 14, entitled, “C/EBPβ cooperates with MYB to maintain the oncogenic program of AML cells." @uni_muenster DOI - https://t.co/fzl5bTnDY2 #cancer #aml #research #openaccess #publishing #o
RT @Oncotarget: #PressRelease: On March 11, 2023, researcher Karl-Heinz Klempnauer from @uni_muenster published a new editorial perspective…
#PressRelease: On March 11, 2023, researcher Karl-Heinz Klempnauer from @uni_muenster published a new editorial perspective in #Oncotarget, entitled, “C/EBPβ cooperates with MYB to maintain the oncogenic program of AML cells” DOI: https://t.co/fzl5bTnDY2
Oncotarget recently #published this #editorial perspective in Volume 14, entitled, “C/EBPβ cooperates with MYB to maintain the oncogenic program of AML cells." @uni_muenster DOI - https://t.co/fzl5bTnDY2 #cancer #aml #research #openaccess #publishing #o
#PaperoftheDay: "C/EBPβ cooperates with MYB to maintain the oncogenic program of AML cells" https://t.co/fzl5bTnDY2 #cancerresearch #oncology #OA #MedEd
NEW #PaperoftheDay: "C/EBPβ cooperates with MYB to maintain the oncogenic program of AML cells" https://t.co/fzl5bTnDY2 #oncology #openaccess #peerreviewed #medEd #OA